Skip to main content

Black Diamond Therapeutics, Inc.

For the period ended Sep 30, 2025. Filed Nov 6, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 6, 2025

BDTX$1.60-14.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)

(in thousands, except share and per share data)

Three Months EndedSeptember 30,Nine Months EndedSeptember 30,
2025202420252024
License revenue$—$—$70,000$—
Operating expenses:
Research and development$7,437$12,914$27,262$39,015
General and administrative3,5415,21612,60621,491
Total operating expenses10,97818,13039,86860,506
Income (loss) from operations(10,978)(18,130)30,132(60,506)
Other income (expense):
Interest income1,1645162,8771,617
Other income (expense)1,3162,0574,4745,198
Total other income (expense), net2,4802,5737,3516,815
Net income (loss)$(8,498)$(15,557)$37,483$(53,691)
Net income (loss) per share - basic$(0.15)$(0.28)$0.66$(0.99)
Net income (loss) per share - diluted$(0.15)$(0.28)$0.65$(0.99)
Weighted average common shares outstanding - basic56,929,10356,507,95656,799,75554,498,037
Weighted average common shares outstanding - diluted56,929,10356,507,95657,480,51254,498,037
Comprehensive income (loss):
Net income (loss)$(8,498)$(15,557)$37,483$(53,691)
Other comprehensive income (loss):
Unrealized gain (loss) on investments, net167222118134
Comprehensive income (loss)$(8,331)$(15,335)$37,601$(53,557)
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.